miR-146a在冠状动脉粥样硬化性心脏病中的研究进展

Research advance on miR-146a in coronary atherosclerotic heart disease

冠状动脉粥样硬化性心脏病在我国呈上升的发展趋势,可导致心肌梗死、心衰、猝死等严重致死性并发症。miR-146a与冠心病的发生发展及治疗预后密切相关,在冠心病模型的冠状动脉内皮细胞、平滑肌细胞及心肌细胞中均有表达,其主要通过作用于相关靶基因和信号通路调节炎症免疫反应、血管形成等。miR-146a对冠心病的危险因素、动脉粥样斑块、冠脉侧支循环、缺血再灌注损伤、药物治疗等方面产生影响,可成为冠心病诊断及治疗的新靶点。本文就miR-146a与冠心病的关系进行阐述,旨在为冠心病临床诊断、治疗及疗效评估提供理论依据。

The incidence of coronary atherosclerotic heart disease （CHD） is increasing in China, which can lead to serious and fatal complications such as myocardial infarction, heart failure, and sudden death. MiR-146a is closely related to the occurrence, development, and prognosis of CHD. It is expressed in endothelial cells, smooth muscle cells, and myocardiocytes of CHD animal models. It mainly regulates inflammatory immune response and angiogenesis by acting on related target genes and signaling pathways. MiR-146a can affect the risk factors of coronary heart disease, atherosclerotic plaque, coronary collateral circulation, ischemia-reperfusion injury, drug treatment, and so on. It can become a new target for the diagnosis and treatment of CHD. This article elaborated the relationship between miR-146a and CHD, aiming to provide a theoretical basis for clinical diagnosis, treatment, and efficacy evaluation of CHD.